Hengsai Biotech Opens Zhongshan R&D Center, Advancing Global DC Vaccine Development

Oct 29, 2024 08:24 CST Updated 08:24

Kousai

Developer of Dendritic Cell Tumor Therapeutic Vaccines

On October 28, the opening ceremony of Hengsai Bio's Zhongshan R&D Center was held at Building 11 of the Zhongshan Life Science Park. Representatives from the Zhongshan Market Supervision Administration, the Cuiheng New District Technology and Finance Bureau, the Cuiheng Group, as well as investors, company representatives, and park representatives including Hengsai Bio and Fuhui Equity Investment Management Co., Ltd., participated in the event.

Cen Zhiyong, a member of the Party Leadership Group of the Zhongshan Market Supervision Administration, congratulated Hengsai Biotech on its opening. He stated that Hengsai Biotech is a leading R&D and production enterprise of dendritic cell vaccines (DC vaccines) in China, and its establishment is of great significance to promoting the development of Zhongshan's biomedicine and health industry. It is hoped that Hengsai Biotech will continue to adhere to innovation-driven development, focus on R&D and production, and make greater contributions to driving industrial growth and improving the health and well-being of the Chinese population.

Chao Hui, member of the Party Committee, director, and deputy general manager of Cuiheng Group, stated that Hengsai Biotech is a demonstration project for Cuiheng Group to implement its investment-driven introduction and production strategy in Cuiheng New District. Its DC vaccine product shows broad market space and wide application prospects. As the investor and park operator, Cuiheng Group will continue to support enterprise development, helping companies like Hengsai Biotech achieve breakthroughs in capital increase and expansion, cost savings, efficiency enhancement, and achievement transformation, promoting the common prosperity of the park and enterprises.

Dr. Hui Ning Liu, founder, chairman and CEO of Hengsai Biotech, expressed her deep gratitude to all parties who have supported the company's development. She stated that the opening of Hengsai Biotech’s Zhongshan R&D Center is an important milestone in the company’s development. Hengsai Biotech will take this as a starting point to accelerate its development process in the Guangdong-Hong Kong-Macao Greater Bay Area. Guided by clinical needs and driven by technological innovation, the company is committed to developing safer, more effective, and affordable DC vaccine products, leading a new wave of global cell therapy.

Hengsai Biotech, founded in 2018, is an innovative technology enterprise dedicated to the research and industrialization of dendritic cell vaccines (DC vaccines) and a national high-tech enterprise. The company has successfully built the Eco-DC Vax platform, aiming to break through industrialization technological barriers and develop safe, efficient, convenient-to-administer, high-quality First-in-Class DC vaccine products with independent intellectual property rights globally.

The company's first pipeline product, KSD-101, has successfully completed dual submissions in China and the United States, receiving the Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). This is China's first original dendritic cell vaccine (DC vaccine) product to receive FDA IND approval. The company has now established stable cooperative relationships with multiple domestic and international research institutions and Class III Grade A hospitals to conduct clinical research and technical collaborations, comprehensively verifying the clinical safety and efficacy of the DC vaccine.

Hengsai Biotech Zhongshan R&D Center is one of the key layouts of Hengsai Biotech's globalization strategy, located on the 2nd floor of Building 11, Zhongshan Life Science Park. Covering an area of approximately 1000 square meters, it includes one central laboratory and two R&D/pilot production workshops. It can meet a series of needs for the research, preparation, and testing of dendritic cell vaccines for IIT clinical studies, while also fulfilling the iterative upgrade requirements of the company’s globally leading Eco-Dc Vax platform. After its activation, it will further enhance the company’s R&D capabilities.